Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a ...

More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

The FDA has freed Rocket Pharmaceuticals from a clinical hold, giving the gene therapy developer permission to take flight ...

The years-long legal kerfuffle between IQVIA and Veeva Systems has come to a close, with the former adversaries ...

The first half of 2025 was brutal for biotech, but investors are still keen on therapeutics in several indications and silver linings exist, particularly for private companies.  | The first half of ...

Partnering with VantAI could give Halda a source of target-effector pairs for its next wave of prospects. The deal could be ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine ...

Opthea’s options may be shrinking as the eye disease biotech comes to terms with a pair of phase 3 failures, but the company ...

In an update to their guidelines for treating high blood pressure, a group of cardiovascular medical societies has included a ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Medtronic has agreed to not only expand the size of its board of directors, but to also task it with taking a closer look at ...